Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kansagra, Ankit J., Frey, Noelle V., Bar, Merav, Laetsch, Theodore W., Carpenter, Paul A., Savani, Bipin N., Heslop, Helen E., Bollard, Catherine M., Komanduri, Krishna V., Gastineau, Dennis A., Chabannon, Christian, Perales, Miguel A., Hudecek, Michael, Aljurf, Mahmoud, Andritsos, Leslie, Barrett, John A., Bachanova, Veronika, Bonini, Chiara, Ghobadi, Armin, Gill, Saar I., Hill, Joshua A., Kenderian, Saad, Kebriaei, Partow, Nagler, Arnon, Maloney, David, Liu, Hien D., Shah, Nirali N., Kharfan-Dabaja, Mohamed A., Shpall, Elizabeth J., Mufti, Ghulam J., Johnston, Laura, Jacoby, Elad, Bazarbachi, Ali, DiPersio, John F., Pavletic, Steven Z., Porter, David L., Grupp, Stephan A., Sadelain, Michel, Litzow, Mark R., Mohty, Mohamad, Hashmi, Shahrukh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268756/
https://www.ncbi.nlm.nih.gov/pubmed/31092900
http://dx.doi.org/10.1038/s41409-019-0451-2

Ejemplares similares

Ejemplares similares